1	Identification of circulating apolipoprotein M as a new determinant of insulin sensitivity
2	and relationship with adiponectin
3	
4	Laurie Frances ¹ , Mikaël Croyal ^{2,3,4} , Jean-Bernard Ruidavets ⁵ , Marie Maraninchi ⁶ , Guillaume Combes ¹ ,
5	Jérémy Raffin ⁷ , Philippe de Souto Barreto ^{5,7} , Jean Ferrières ^{5,8} , Ellen E. Blaak ⁹ , Bertrand Perret ¹ , Cédric
6	Moro ¹ , René Valéro ⁶ , Laurent O. Martinez ^{1, *} , Nathalie Viguerie ^{1, *}
7	
8	¹ Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM,
9	Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
10	² Nantes Université, CHU Nantes, CNRS, INSERM, BioCore, US16, SFR Bonamy, 44000 Nantes, France
11	³ CRNH-Ouest Mass Spectrometry Core Facility, 44000 Nantes, France
12	⁴ Nantes Université, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44000 Nantes, France
13	⁵ CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, 31000 Toulouse, France
14	⁶ Aix Marseille Université, APHM, INSERM, INRAe, C2VN, Department of Nutrition, Metabolic
15	Diseases and Endocrinology, University Hospital La Conception, 13385 Marseille, France
16	⁷ Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse,
17	31000 Toulouse, France
18	⁸ Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of
19	Medicine, Toulouse, France
20	⁹ Department of Human Biology, NUTRIM, School of Nutrition and Translational Research in
21	Metabolism, Maastricht University Medical Centre+(MUMC+), Maastricht, The Netherlands
22	* These authors contributed equally to this work.
23	

24 Contact info :

25	Laurent Martinez, LiMitAging team, INSERM, UMR 1297, 1 Avenue du Pr. Jean Poulhès, BP 84225,
26	31432 Toulouse, France. Tel: +33531224147. <u>ORCID ID: 0000-0002-0985-3152</u> Email:
27	laurent.martinez@inserm.fr
28	Nathalie Viguerie, MetaDiab team, Inserm, UMR 1297, 1 Avenue du Pr. Jean Poulhès, BP 84225,
29	31432 Toulouse, France. Tel: +33561325631. <u>ORCID ID: 0000-0002-1730-9915</u> Email:
30	nathalie.viguerie@inserm.fr
31	
32	Trial registration: NCT01277068, registered 13 January 2011; NCT02332434, registered 5 January
33	2015; and NCT00390637, registered 20 October 2006.
34	
35	Competing interests
36	The authors have no conflicts of interest to declare.

40

41 Abstract

Background. Adiponectin and apolipoprotein M (apoM) are adipokines indicatives of healthy adipose tissue and down-regulated with obesity. We compared circulating apoM with adiponectin regarding their relationship with metabolic parameters and insulin sensitivity and examined their gene expression patterns in adipocytes and in the adipose tissue.

Methods. Circulating apoM and adiponectin were examined in 169 men with overweight in a crosssectional study, and 13 patients with obesity during a surgery-induced slimming program. Correlations with clinical parameters including the insulin resistance index (HOMA-IR) were analyzed. Multiple regression analyses were performed on HOMA-IR. The *APOM* and *ADIPOQ* gene expression were measured in the adipose tissue from 267 individuals with obesity and a human adipocyte cell line.

52 **Results.** Participants with type 2 diabetes had lower circulating adjoenectin and apoM, while apoM 53 was higher in individuals with dyslipidemia. Similar to adiponectin, apoM showed negative 54 associations with HOMA-IR and hs-CRP (r>-0.2), and positive correlations with HDL markers (HDL-C 55 and apoA-I, r>0.3). Unlike adiponectin, apoM was positively associated with LDL markers (LDL-C and 56 apoB100, r< 0.20) and negatively correlated with insulin and age (r>-0.2). The apoM was the sole 57 negative determinant of HOMA-IR in multiple regression models, while adiponectin not contributing 58 significantly. After surgery, the change in HOMA-IR was negatively associated with the change in 59 circulating apoM (r=-0.71), but not with the change in adiponectin. The APOM and ADIPOQ gene 60 expression positively correlated in adipose tissue (r>0.44) as well as in adipocytes (r>0.81). In 61 adipocytes, APOM was downregulated by inflammatory factors and upregulated by adiponectin.

62 **Conclusions.** The apoM rises as a new partner of adiponectin regarding insulin sensitivity. At the 63 adipose tissue level, the adiponectin may be supported by apoM to promote a healthy adipose 64 tissue.

65

66 Introduction

Obesity is a global concern as excessive body fat is linked to metabolic syndrome, type 2 diabetes (T2D), and cardiovascular diseases [1]. Adipose tissue (AT) produces various factors, including numerous adipokines with local and broad systemic effects on whole-body homeostasis [2].

Most adipokines are secreted at higher levels with increasing fat and play a detrimental role in the development of metabolic disorders associated with obesity [2]. Conversely, few adipokines, like adiponectin, are inversely associated with body fat [2]. Adiponectin is an adipose-specific protein, encoded by *ADIPOQ*, which blood concentration decreases with obesity, metabolic syndrome, or T2D [3]. Adiponectin possesses anti-inflammatory, anti-diabetic, anti-atherogenic, and cardioprotective properties [4].

Recently, apolipoprotein M (apoM), predominantly produced by the liver and kidney, was found to be secreted by adipocytes [5]. Gene expression of *APOM* in AT is lower in individuals with high body fat, metabolic syndrome, or insulin resistance (IR) compared to lean healthy individuals [5]. Accordingly, blood levels of apoM are reduced in obesity, metabolic syndrome, and T2D [6-8]. Overall, apoM is an adipokine that exhibits a similar expression profile in AT and in the circulation to that of adiponectin [9]. Therefore, we hypothesized that both adiponectin and apoM could similarly predict changes in insulin sensitivity.

83 In this study, we conducted a comparative analysis of these two beneficial adipokines concerning 84 obesity-related disorders, with a particular focus on glucose homeostasis. We investigated whether 85 their blood concentrations were associated with lipid and glucose homeostasis parameters, and

86 whether they could contribute to insulin sensitivity. Furthermore, we explored the relationship
87 between apoM and adiponectin at the level of the adipocyte.

88

89 Methods

90 Study participants

The studies, referred as cohorts A, B and C, were conducted in accordance with the ethical principles of the Declaration of Helsinki. Before any procedure, all participants received oral information and signed a written informed consent form before they participated in any of the study procedures. Figure S1 illustrates the participants' flowchart.

95 **Cohort A:** The protocol received approval from the local ethics committee (CCPPRB, 96 Toulouse/Sud-Ouest, file #1-99-48, Feb 2000). The biological sample collection was registered as DC-97 2008-463 #1 to the Ministry of Research and to the Regional Health authority. Cohort A consisted of 98 male participants selected from the Genetique et ENvironnement en Europe du Sud (GENES) cross-99 sectional case-control study. In this ancillary analysis, the patients with coronary artery disease (CAD) 100 (referred to as cases) were age-matched to individuals without CAD (controls), and apoM was 101 quantified using a multiplex liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 102 [10]. Subjects with missing data for fasting serum insulin and adiponectin levels were excluded, 103 resulting in a final sample of 169 participants (mean age 60.6 years [SD, 8.1]), comprising 102 104 controls and 67 cases. Detailed procedures have been reported previously [11]. Anthropometric 105 measurements, including fat mass assessment using Bioimpedance, and clinical variables were 106 recorded. Venous blood was sampled after an overnight fast. Standardized interviews, conducted by 107 a single physician, gathered information on environmental characteristics, medical history, and 108 cardiometabolic risk factors. Alcohol consumption was calculated as the sum of different types of 109 drinks. Physical activity was assessed using a standardized questionnaire and categorized into two 110 levels: "high" if physical activity was performed for ≥ 20 min twice a week, or "low" if physical activity 111 was performed for < 20 min once a week or less. Dyslipidemia was defined as treatment with drugs

or fasting serum total cholesterol ≥ 2.50 g/L as described in [12]. Hypertension was defined as treatment with drugs or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.

114 T2D was defined as treatment with drugs or fasting blood glucose \geq 7.0 mmol/L.

115 **Cohort B:** The approval was received by the Research Ethics Board of Aix-Marseille University 116 (NCT01277068 and NCT02332434). Cohort B comprised 13 individuals with obesity of both sexes 117 (77% women) with a mean age of 37.6 years [SD, 9.1], who underwent sleeve gastrectomy at the 118 General and Endocrine Surgery Department of La Conception Hospital (Marseille, France), as 119 previously described [13]. The clinical evaluation and laboratory tests were conducted at the 120 Nutrition Department of La Conception Hospital. Patients were examined one month before 121 (baseline) and one year after gastric sleeve surgery to reach steady weight loss. Each visit included 122 measuring anthropometric parameters and blood sampling after an overnight fast [13].

123 Cohort C: This study is part of the Diet, Obesity, and Genes (DiOGenes) trial, which involved 124 individuals with overweight or obesity recruited between 2005 and 2007 in 8 European countries 125 [14]. The protocol received approval from the ethical boards of each of the 8 centers (NCT00390637). 126 For the present study, a subgroup of 267 individuals (95 men and 172 women) with a mean age of 127 42.7 years [SD, 6.4]) was selected. Anthropometric measurements, blood sampling and subcutaneous 128 abdominal AT needle biopsies were performed after an overnight fast. Clinical measures and 129 subcutaneous abdominal AT samples were analysed at baseline (before any intervention), as 130 described in [15].

131

132 Biochemical analyses

Fasting blood glucose, triglycerides (TG), cholesterol, high-density lipoprotein-cholesterol (HDL-C),
γ-glutamyltransferase (γ-GT), and high-sensitivity C-reactive protein (hs-CRP) were assayed with
enzymatic reagents on an automated analyzer (Hitachi 912 and Cobas[®] Analyzer, Roche Diagnostics).
Low-density lipoprotein-cholesterol (LDL-C) was calculated using the Friedewald formula. The
estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease

138 Epidemiology Collaboration (CKD-EPI) equation. Insulin concentration was measured bv 139 electrochemiluminescence immunoassay (Advia Centaur, Siemens Healthineers, cohort A and Cobas® 140 Analyzer, Roche Diagnostics, cohort B). IR was assessed using the Homeostasis Model Assessment of 141 Insulin Resistance (HOMA-IR) index, calculated as [fasting glucose (mM) x fasting insulin 142 (mU/L)/22.5]. Adiponectin serum levels were measured using a specific enzyme-linked 143 immunosorbent assay kit (Quantikine[®] Human Adiponectin, R&D Systems). Apolipoprotein A-I (apoA-144 I), apolipoprotein B100 (apoB100), and apolipoprotein C-III (apoC-III) were determined by 145 immunoturbidimetric assay on an automated analyzer (Cobas® Analyzer, Roche Diagnostics, Cohort 146 A) and by immunonephelometric assay (Roche Diagnostics) using a BN ProSpec analyzer (Siemens 147 Healthineers). ApoM was measured by the LC-MS/MS method, as described previously [13].

148

149 Cell culture

150 Cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. Human multipotent 151 adipose-derived stem cells (hMADS) were cultivated as described in [5]. Briefly, hMADS cells were 152 differentiated for 13 days in 50/50 DMEM 1g/L glucose (Sigma-Aldrich) and Ham's F-12 (Lonza) 153 medium, with 125 nM transferrin, 10 nM insulin, 0.2 nM triiodothyronine, 100 µM 3-isobutyl-1-154 methylxanthine (IBMX), 1 μ M dexamethasone (Sigma-Aldrich), and 100 nM rosiglitazone (Cayman). 155 ThP-1 monocytes were cultured in RPMI-1640 medium containing 10% FBS, 1 mM sodium pyruvate, 156 50 μM 2-mercaptoethanol (Invitrogen), and 36 mM glucose (Sigma-Aldrich). For differentiation into 157 M0 macrophages, the cells were seeded in a serum-free, 2-mercaptoethanol-free RPMI medium 158 containing 100 nM 12-phorbol-13-myristate acetate (Sigma-Aldrich) for 48h. Macrophages were then 159 polarized for 3 days, inducing the M2-like anti-inflammatory phenotype with 20 ng/mL IL-4 (Sigma-160 Aldrich) or the M1-like pro-inflammatory phenotype with 2 ng/mL Escherichia coli lipopolysaccharide 161 and 10 ng/mL IFNy (Sigma-Aldrich).

162

163 Cell treatment

After 10 days of differentiation, the hMADS cells were treated with recombinant globular adiponectin (PeproTech), or CRP (Merck Millipore) or exposed to 50/50 conditioned media from M1like or M2-like polarized ThP-1 for 72 hours. The cells were transduced with AAVs vectors (serotype 8) encoding either apoM or mCherry (designed and produced by the Vectorology platform of the Cancerology Research Center of Toulouse, Inserm UMR1037) for 72 hours, as described in [16]. Subsequently, cells were lysed using RLT buffer (Qiagen) containing 1% 2-mercaptoethanol (Sigma-Aldrich), flash frozen and stored at -80°C.

171

172 Gene expression

173 RNA was extracted using a Rneasy mini kit (Qiagen) following manufacturer's instructions. Total 174 RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen). Real-time PCR 175 was performed using Tagman probes or SyberGreen primers assays with a QuantStudio 5 Real-Time 176 PCR system (Applied Biosystems). For the AT samples, expression of APOM (Hs00219533 m1) or ADIPOQ (Hs00605917 m1) data were normalized to PUM1 (Hs00472881 m1). For the hMADS cells, 177 178 expression of APOM or ADIPOQ (forward GCAGAGATGGCACCCCTG, reverse 179 GGTTTCACCGATGTCTCCCTTA) were normalized to LRP10 (Hs01047362 m1).

180

181 Statistical analyses

182 The categorical parameters are expressed as numbers (%) and the quantitative parameters as 183 means \pm the standard deviation (SD). Shapiro–Wilks test was used to examine the normality of 184 distribution of residuals and Levene's test to determine the homogeneity of the variances. When 185 comparing cases to controls or baseline versus after surgery, the mean values of the quantitative 186 variables were analyzed by Student's t-test. When the basic assumptions of Student's t-test were not 187 satisfied, the data were logarithmically transformed or subjected to a Wilcoxon-Mann-Whitney test. 188 Associations of apoM, adiponectin, and HOMA-IR with anthropometric parameters, biological 189 markers, and environmental factors were tested using Spearman's rank correlations with P-value

adjustment using false discovery rate. For regression analyses of HOMA-IR, a backward stepwise selection was used. The F-statistics for a variable to stay in the model had to be significant at P <0.10. Variables were maintained in the model when the F-statistic was significant at P < 0.05. For each quantitative variable, regression analyses were performed with polynomial models to look for possible nonlinear relationships with dependent variables. Lack of multicollinearity was assessed by examining the variance inflation factors in the final models.

196

197 Results

198 Circulating adiponectin versus apoM relationship with cardiometabolic status

The clinical and biological characteristics of cohort A are presented in Table S1. Cohort A comprised overweight men (BMI, 26.7 kg/m², [SD, 3.5]), of who 39.6% were patients with CAD (cases).

202 Compared with the control participants, the CAD patients had less physical activity and were 203 diagnosed or treated more often for hypertension, dyslipidemia, or T2D, with a larger proportion 204 suffering from T2D (25.4% versus 6.9% in the controls). The body fat mass percentage and waist 205 circumference were also higher in cases than in the controls. Among the biological markers, the 206 levels of total cholesterol and LDL-C were lower in cases, probably reflecting the effects of lipid-207 lowering drugs in patients. However, individuals with CAD displayed higher levels of TG, hs-CRP, and 208 y-GT. HDL markers (HDL-C and apoA-I) were lower. Finally, the cases exhibited higher HOMA-IR and 209 lower adiponectin levels than the control participants, while the apoM levels were similar between 210 the two groups.

Blood levels of apoM and adiponectin were then considered according to other disease conditions, including T2D, dyslipidemia, and hypertension (Table S2). Adiponectin and apoM levels were lower in participants diagnosed or treated for T2D. Unlike adiponectin, apoM levels were lower in participants with hypertension, while they were higher in subjects with dyslipidemia than in the individuals without these conditions. These observations were weakened when only the treatment

conditions were considered (Table S3), except for adiponectin, for which the levels were lower in
 participants treated for dyslipidemia and T2D.

218

219 Circulating apoM is a negative determinant of insulin resistance

220 Correlations between circulating levels of apoM and biological and clinical parameters relative to 221 cardiovascular and T2D risk factors were investigated in the entire study population (cohort A). These

222 correlations were compared with equivalent correlation for adiponectin and HOMA-IR (Table 1).

223 The blood level of apoM did not show any significant correlation with that of adiponectin. 224 However, similar to adiponectin, apoM exhibited a negative association with hs-CRP (r=-0.28) and 225 HOMA-IR (r=-0.29), while it was positively associated with HDL markers (r=0.32, for both HDL-C and 226 apoA-I). Unlike adiponectin, apoM did not correlate with TG, but it was positively associated with 227 total cholesterol (r=0.36), LDL markers (LDL-C and apoB100, r=0.27; and r=0.20, respectively), and 228 apoC-III (r=0.19). No association was observed between apoM and cardiac functions (systolic blood 229 pressure, heart rate), or environmental factors (smoking, physical activity), except for a positive 230 correlation between apoM and alcohol consumption (r=0.19). Of note, apoM was negatively 231 associated with fat mass (r=-0.26) and age (r=-0.28).

In addition to the expected negative correlations with apoM and adiponectin, HOMA-IR displayed
 negative correlations with HDL markers (apoA-I and HDL-C) and physical activity and positive
 correlations with adiposity markers (BMI, fat mass, and waist circumference), TG, apoC-III, hs-CRP,
 and γ-GT (Table1).

To further identify the determinants of IR among these variables associated with HOMA-IR, we conducted a multiple regression analysis with HOMA-IR as the dependent variable. The model included apoM and adiponectin as potent explanatory variables, along with BMI, waist circumference, physical activity, TG, HDL-C, hs-CRP, γ -GT, apoC-III, apoB100, T2D, dyslipidemia, hypertension, and case-control status. This model explained 39% of the variability in HOMA-IR and revealed that diabetes status and four variables were determinants of HOMA-IR variability, which

included apoM but not adiponectin (Table 2). Among the identified determinants, waist circumference and γ -GT showed the strongest positive associations with HOMA-IR, explaining 13.6% and 9.6% of the variability, respectively. In contrast, apoM displayed an inverse association, accounting for 5.6% of the variability in HOMA-IR. Notably, no significant interaction between apoM and case-control status was observed (*P*=0.58). Furthermore, even after removing apoM from the set of variables at entry, adiponectin still did not contribute to the variability of HOMA-IR (data not shown).

249

250 Increased circulating apoM is closely related to insulin resistance relief after sleeve gastrectomy

251 To further study the association between apoM and IR, we examined the changes in circulating 252 apoM after sleeve gastrectomy in patients with obesity and analyzed their correlation with the 253 improvement in HOMA-IR. Anthropometric and biochemical characteristics of these patients at 254 baseline (*i.e.*, before gastric sleeve surgery) and one year after surgery are presented in Table S4. 255 One year after surgery, all individuals showed a decrease in adiposity markers (BMI, fat mass, and 256 waist circumference) and displayed an improved lipid profile, including reduced atherogenic lipids 257 (TG and LDL-C) and increased HDL markers (HDL-C and apoA-I). Additionally, there was a significant 258 decrease in HOMA-IR (from 4.26, [SD, 1.49] to 1.39, [SD, 0.69]) and an increase in adiponectin levels 259 (from 5.54 µg/L, [SD, 1.61] to 10.47 µg/L [SD, 4.07]). Circulating levels of apoM were not significantly 260 changed (Table S4); however, we found a strong inverse relationship between the changes in HOMA-261 IR and changes in circulating apoM (r=-0.71), while no significant association was observed with 262 changes in adiponectin (Figure 2). Of note, there was a trend of a positive correlation between 263 changes in circulating apoM and changes in adiponectin (r=0.57, P=0.08, not shown).

264

265 Positive association between ADIPOQ and APOM mRNA level in AT

We compared the gene expression of adiponectin and apoM in human subcutaneous AT from individuals with overweight or obesity (cohort C, Figure 2A and Table S5). *ADIPOQ* gene expression in

- AT was higher than APOM gene expression and both were positively correlated (Figure 2A, r=0.441).
- Additionally, HOMA-IR negatively correlated with AT expression of ADIPOQ (r=0.147, Figure 2B), and
- 270 APOM gene expression in AT (r=-0.1226, Figure 2C).
- 271

272 Inflammatory factors downregulate ADIPOQ and APOM expression in adipocytes

273 Due to the close association of IR with AT inflammation, we aimed to mimic the impact of 274 inflammatory conditions on ADIPOQ and APOM expression in adipocytes. We treated hMADS 275 adipocytes with conditioned media from pro-inflammatory M1-like or anti-inflammatory M2-like 276 polarized ThP-1 macrophages. The former media led to down-regulation of both ADIPOQ and APOM 277 gene expressions (Figure 3A). A strong correlation between ADIPOQ and APOM gene expression was 278 observed in these adipocytes (r=0.91, Figure 3B). Similarly, a treatment with CRP also downregulated 279 the expression of ADIPOQ and APOM genes in hMADS cells (Figure 3C), while the positive correlation 280 between ADIPOQ and APOM mRNA levels persisted under this condition (r=0.82, Figure 3D).

281

282 Adiponectin promotes APOM expression in adipocytes

Adipocytes express specific adiponectin receptors, whereas apoM lacks known specific receptor. To further investigate the relationship between the two adipokines, we examined the effect of adiponectin on *APOM* gene expression. Treating hMADS adipocytes with increasing concentrations of adiponectin resulted in a dose dependent increase in *APOM* expression, with a mean 1.6-fold [SD, 0.9]) rise at 1µM adiponectin (Figure 4).

288

289 Discussion

Here, we explored the relationship between the circulating concentrations of two beneficial adipokines, namely adiponectin and apoM, and cardiometabolic parameters in high-risk populations.

292 We also examined the relationship between the two adipokines at the adipose level.

Firstly, despite the strong correlation of *APOM* and *ADIPOQ* gene expression in adipocytes and AT, the apoM concentration did not correlate with that of adiponectin, as a hallmark of their distinct tissue origin. While their respective circulating levels were lower in participants with T2D, their level may still reflect distinct cardiometabolic states.

As anticipated, our study validated previously reported associations between blood levels of 297 298 adiponectin and lipids [17, 18]. Adiponectin displayed an inverse correlation with TG and a positive 299 association with HDL markers such as HDL-C and apoA-I. In contrast, the circulating apoM level was 300 not associated with plasma TG but displayed a positive correlation with both anti-atherogenic HDL 301 (HDL-C, apoA-I) and atherogenic LDL (LDL-C, apoB100) markers. This association of apoM with both 302 HDL and LDL markers has been reported previously [6, 19] and is likely due to the fact that apoM is 303 transported by both HDL and LDL rather than having a specific role in lipoprotein metabolism [19]. 304 However, it is important to note that apoM is predominantly transported by HDL, and a recent report 305 has shown that low plasma apoM is independently associated with heart failure [20]. This suggest 306 that apoM may play a role in some HDL cardioprotective functions [9].

307 An expected reduced level of adiponectin was found in patients with CAD [17]. In humans, the 308 ADIPOQ gene, located on chromosome 3q27, contains polymorphisms that influence the level and 309 activity of adiponectin, SNP 276 (G>T) and I164T. The former is associated with obesity, IR, and T2D 310 [21], while the latter is a missense mutation associated with metabolic syndrome and CAD [22]. There 311 is consistent evidence of an inverse relationship between plasma adiponectin and metabolic 312 syndrome, low-grade inflammation, T2D, and cardiovascular risk [23-25]. Of note, circulating 313 adiponectin has paradoxically been associated with increased all-cause and cardiovascular mortality 314 [26, 27]. Adiponectin resistance in vessels might be a clue to explain this unexpected outcome on the 315 prognostic value of circulating adiponectin [27].

ApoM concentration was found to be higher in participants with dyslipidemia, consistent with previous studies [8]. This observation aligns with the previously mentioned positive association of apoM with LDL-C. Interestingly, the relationship between apoM and dyslipidemia status was no

319 longer observed when only the treated patients (the majority of whom were on statin treatment) 320 were considered among the subjects with dyslipidemia. This is consistent with the effect of statins in 321 lowering apoM levels [6]. Additionally, apoM levels were lower in subjects with hypertension, in 322 accordance with its role in reducing blood pressure in hypertensive mice [28].

323 Similarly to APOM expression in AT [5] and consistent with previous reports [18, 20], circulating 324 apoM was found to be negatively associated with body fat and hs-CRP level, a biomarker of systemic 325 inflammation. Additionally, our in vitro studies on adipocytes indicate that conditions mimicking an 326 inflammatory context, including treatments with conditioned media from pro-inflammatory 327 macrophages or CRP, down-regulate APOM gene expression. This is in line with our previous study 328 reporting a negative effect of TNF α on APOM gene expression in adipocytes [5]. This suggests that a 329 low circulating apoM may serve as a potential marker of systemic inflammation and dysfunctional 330 AT.

331 While adiponectin is a key adipokine in preventing metabolic syndrome and associated 332 pathologies, much less is known about apoM, especially regarding its expression in adipocytes. ApoM 333 is distributed in various tissues, with primary expression in hepatocytes and proximal tubular kidney 334 cells, and to a lesser extent in endothelial cells and adipocytes [9, 29]. The human APOM gene is 335 located on chromosome 6p21.33. There is evidence that T-778C polymorphism in the proximal 336 promoter region of the APOM gene confers susceptibility to the development of T2D [30]. Another 337 variant, rs1266078, resulted in an 11% lower circulating apoM, but no association was found with the 338 risk of T2D [31]. Similar to adiponectin, we found a lower level of apoM in participants with T2D and 339 an inverse association with IR. Surprisingly, in a multiple linear regression model, the apoM level in 340 cohort A was the only negative determinant of HOMA-IR, independently of coronary status, while 341 adiponectin did not contribute to the variability of HOMA-IR. This indicates that in men with 342 overweight, blood apoM has a stronger association to HOMA-IR than circulating adiponectin.

To investigate the relationship between these two adipokines and IR, we examined whether weight-reduction surgery in patients with obesity (cohort B) could influence the levels of apoM and

345 its association with IR. As reported elsewhere, patients with obesity (cohort B, baseline) exhibited 346 lower circulating levels of adiponectin [32] and apoM [33] compared to individuals with overweight 347 (cohort A), consistent with the previously mentioned negative association of plasma adiponectin and 348 apoM with fat mass. Bariatric surgery offers an efficient approach for managing obesity, with various 349 surgical procedures available [34]. Among these, sleeve gastrectomy accounts for 55.4% of all 350 bariatric surgeries thanks to its minimal invasiveness [35] and has been shown to resolve IR and T2D 351 [36]. In our study, one year after sleeve gastrectomy, all patients exhibited a HOMA-IR below 2.5 and 352 a two-fold increase in adjonectin concentration. The minor increase (+13%) in apoM levels did not 353 reach statistical significance (P > 0.1). Circulating apoM has been reported to be filtered then taken 354 up from urine by tubular kidney cells via the megalin receptor [37]. Given that people with class 3 355 obesity (BMI>40 kg/m²) often present kidney disease that could be alleviated after sleeve 356 gastrectomy, one might expect an increase in plasma apoM levels associated with improved renal 357 function. However, the patients of Cohort B had mild CKD as measured by eGFR, and no significant 358 change in eGFR was found, in line with a recent report [38]. Conversely, improvement in insulin 359 sensitivity following surgery was strongly associated with increase in circulating apoM. This reciprocal 360 correlation between apoM and HOMA-IR suggests that increased circulating apoM could improve 361 glucose homeostasis by reducing IR. This provides additional evidence that, in complement to 362 adiponectin, apoM may be an additional beneficial factor of glycaemic control.

Next, we examined the relationship between adiponectin and apoM at the AT level. For the first time, we reported here a strong positive correlation between *ADIPOQ* and *APOM* gene expression in human AT and adipocytes, independently of the inflammatory context. Interestingly, adiponectin was found to promote the expression of *APOM* in adipocytes. Although further studies are needed to identify the pathways regulating apoM expression and secretion in adipocytes, our observations suggest a positive feedback loop between adiponectin and apoM that controls local AT inflammation and might help prevent insulin sensitivity decline. Considering the importance of AT inflammation in

370 systemic IR [4], our study suggests that the adipose apoM might play a noticeable role in maintaining

a healthy AT environment and promoting systemic insulin sensitivity, alongside with adiponectin.

372 Several limitations of this study warrant mention. Firstly, we focused solely on one form of 373 circulating adiponectin. Considering that the high molecular weight isoform is considered as the 374 active form [32], further investigations to explore isoform specificity would be necessary. Secondly, 375 additional studies are required to determine if AT is a significant site of apoM production and to 376 understand the mechanism through which apoM may contribute to preventing IR.

In conclusion, the present study examined for the first time the relative contributions of adiponectin and apoM regarding insulin sensitivity. We found a close relationship between adipose apoM and adiponectin, and that plasma apoM, but not adiponectin, was a negative explanatory variable of HOMA-IR, independently of coronary status. The stronger relationship of insulin sensitivity with apoM rather than adiponectin was unexpected. This establishes apoM as a novel factor associated to insulin sensitivity.

383

384 Acknowledgments

385 We are grateful to all individuals participating in this study. This research was funded by the Region

386 Occitanie Pyrénées-Méditerranée (GRAINE HEPATOCARE, Reference number: no. 19014226), Inserm,

387 Toulouse 3 University, and grants from Société Française de Nutrition. L.F. was supported by a Ph.D.

388 fellowship from Region Occitanie Pyrénées-Méditerranée and Inserm.

389

390 Author Contributions

391 Conceptualization, L.O.M. and N.V.; methodology, LO.M., L.F., G.C., J.F., B.P., E.E.B, R.V., M.C., and

392 N.V.; formal analysis, J.B.R. and M.M.; data curation, L.F., J.B.R., J.R., and M.C.; draft preparation,

- 393 L.O.M. and N.V.; review and editing, L.F., J.B.R., M.M., G.C., J.R, P.S.R., J.F.; B.P.; C.M.; R.V.; M.C.,
- 394 E.E.B, L.O.M, and N.V.; supervision, L.O.M. and N.V.; funding acquisition, L.O.M. and N.V..

396 Competing Interests

397 The authors have no conflicts of interest to declare.

398

- 399 Data Availability
- 400 The datasets are available from the corresponding authors on reasonable request.

402	References
403	
404 405 406	 Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. International journal of molecular sciences 2019; 20(9).
407 408 409	2. Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. <i>Nature reviews. Endocrinology</i> 2019; 15 (9): 507-524.
410 411 412	3. Maeda N, Funahashi T, Matsuzawa Y, Shimomura I. Adiponectin, a unique adipocyte-derived factor beyond hormones. <i>Atherosclerosis</i> 2020; 292: 1-9.
413 414 415 416	4. Li X, Zhang D, Vatner DF, Goedeke L, Hirabara SM, Zhang Y et al. Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice. Proceedings of the National Academy of Sciences of the United States of America 2020; 117(51): 32584-32593.
417 418 419 420	5. Sramkova V, Berend S, Siklova M, Caspar-Bauguil S, Carayol J, Bonnel S <i>et al</i> . Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction. <i>The American</i> <i>journal of clinical nutrition</i> 2019; 109 (6): 1499-1510.
421 422 423 424	6. Kappelle PJ, Ahnstrom J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BH <i>et al</i> . Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. <i>Atherosclerosis</i> 2010; 213 (1): 247-250.
425 426 427 428	7. Li T, Yang L, Zhao S, Zhang S. Correlation Between Apolipoprotein M and Inflammatory Factors in Obese Patients. <i>Medical science monitor : international medical journal of experimental and clinical research</i> 2018; 24: 5698-5703.
429 430 431 432	8. Zhang P, Gao J, Pu C, Feng G, Wang L, Huang L <i>et al.</i> Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case- control study. <i>Lipids in health and disease</i> 2016; 15 (1) : 158.
433 434 435	9. Tavernier G, Caspar-Bauguil S, Viguerie N. Apolipoprotein M: new connections with diet, adipose tissue and metabolic syndrome. <i>Current opinion in lipidology</i> 2020; 31 (1): 8-14.
436 437 438 439	10. Genoux A, Duparc T, Ruidavets JB, Ingueneau C, Najib S, Ferrieres J <i>et al</i> . A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: Comparison with conventional ELISA. <i>Talanta</i> 2020; 219: 121300.
440 441 442 443	11. Genoux A, Ruidavets JB, Ferrieres J, Combes G, Lichtenstein L, Pons V <i>et al.</i> Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study. <i>Journal of lipid research</i> 2013; 54 (9): 2550-2558.
444	

445 446 447	12. Roeykens J, Rogers R, Meeusen R, Magnus L, Borms J, de Meirleir K. Validity and reliability in a Flemish population of the WHO-MONICA Optional Study of Physical Activity Questionnaire. <i>Med Sci Sports Exerc</i> 1998; 30 (7): 1071-1075.
448 449 450 451	13. Poirier J, Cloteau C, Aguesse A, Billot X, Thevenot E, Krempf M <i>et al</i> . Bariatric Surgery Improves the Atherogenic Profile of Circulating Methylarginines in Obese Patients: Results from a Pilot Study. <i>Metabolites</i> 2021; 11 (11).
452 453 454 455	14. Larsen TM, Dalskov SM, van Baak M, Jebb SA, Papadaki A, Pfeiffer AF <i>et al.</i> Diets with high or low protein content and glycemic index for weight-loss maintenance. <i>The New England journal of medicine</i> 2010; 363 (22): 2102-2113.
456 457 458 459	15. Bolton J, Montastier E, Carayol J, Bonnel S, Mir L, Marques MA <i>et al.</i> Molecular Biomarkers for Weight Control in Obese Individuals Subjected to a Multiphase Dietary Intervention. <i>The</i> Journal of clinical endocrinology and metabolism 2017; 102 (8): 2751-2761.
460 461 462 463	16. Jimenez V, Munoz S, Casana E, Mallol C, Elias I, Jambrina C <i>et al</i> . In vivo adeno-associated viral vector-mediated genetic engineering of white and brown adipose tissue in adult mice. <i>Diabetes</i> 2013; 62 (12): 4012-4022.
464 465 466 467	17. Hascoet S, Elbaz M, Bongard V, Bouisset F, Verdier C, Vindis C <i>et al</i> . Adiponectin and long-term mortality in coronary artery disease participants and controls. <i>Arteriosclerosis, thrombosis,</i> and vascular biology 2013; 33 (1): e19-29.
468 469 470 471	18. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. <i>Diabetes care</i> 2004; 27 (7): 1680-1687.
472 473 474 475	19. Christoffersen C, Benn M, Christensen PM, Gordts P, Roebroek AJM, Frikke-Schmidt R <i>et al</i> . The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. <i>Journal of lipid research</i> 2012; 53 (10): 2198-2204.
476 477 478 479	20. Chirinos JA, Zhao L, Jia Y, Frej C, Adamo L, Mann D <i>et al.</i> Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. <i>Circulation</i> 2020; 141 (18): 1463- 1476.
480 481 482 483 484	21. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S <i>et al.</i> Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. <i>Hum Mol Genet</i> 2002; 11 (21): 2607-2614.
485 486 487 488	22. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S <i>et al</i> . Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. <i>Journal of</i> <i>the American College of Cardiology</i> 2004; 43 (7): 1195-1200.
489	

490 491 492	 Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM <i>et al.</i> Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. <i>Diabetes</i> 2004; 53(9): 2473-2478.
493 494 495 496	24. Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. <i>Int J Obes (Lond)</i> 2007; 31 (2): 213-220.
497 498 499	25. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. <i>Clin Sci (Lond)</i> 2006; 110 (3): 267-278.
500 501 502 503	26. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. <i>Atherosclerosis</i> 2012; 220 (2) : 587-592.
504 505 506	27. Wang Y, Ma XL, Lau WB. Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification. <i>Trends in endocrinology and metabolism: TEM</i> 2017; 28 (7): 519-530.
507 508 509	28. Swendeman SL, Xiong Y, Cantalupo A, Yuan H, Burg N, Hisano Y <i>et al</i> . An engineered S1P chaperone attenuates hypertension and ischemic injury. <i>Science signaling</i> 2017; 10 (492).
510 511 512	29. Bisgaard LS, Christoffersen C. Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology. <i>Current opinion in lipidology</i> 2019; 30 (3): 212-217.
513 514 515 516 517	30. Niu N, Zhu X, Liu Y, Du T, Wang X, Chen D <i>et al.</i> Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. <i>Diabetes/metabolism research and reviews</i> 2007; 23 (1): 21-25.
518 519 520 521	31. Liu D, Pan JM, Pei X, Li JS. Interaction Between Apolipoprotein M Gene Single-Nucleotide Polymorphisms and Obesity and its Effect on Type 2 Diabetes Mellitus Susceptibility. Scientific reports 2020; 10 (1): 7859.
522 523 524	32. Wang ZV, Scherer PE. Adiponectin, the past two decades. <i>Journal of molecular cell biology</i> 2016; 8 (2): 93-100.
525 526 527 528	33. Ooi EM, Watts GF, Chan DC, Nielsen LB, Plomgaard P, Dahlback B <i>et al</i> . Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. <i>Atherosclerosis</i> 2010; 210 (1): 326-330.
529 530 531 532	34. Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. <i>Nature medicine</i> 2012; 18 (6): 950-955.
533	

534 535	35. Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L. Bariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters. <i>Obes Surg</i> 2021; 31 (5): 1937-1948.
536 537	36. Salman AA, Salman MA, Marie MA, Rabiee A, Helmy MY, Tourky MS et al. Factors associated with
538 539	resolution of type-2 diabetes mellitus after sleeve gastrectomy in obese adults. <i>Scientific reports</i> 2021; 11 (1): 6002.
540	
541	37. Bisgaard LS, Christoffersen C. The apoM/S1P Complex-A Mediator in Kidney Biology and Disease?
542	Front Med (Lausanne) 2021; 8: 754490.
543	
544	38. Kassam AF, Taylor ME, Morris MC, Watkins BM, Thompson JR, Schauer DP et al. The impact of
545	sleeve gastrectomy on renal function in patients with chronic kidney disease varies with
546	severity of renal insufficiency. <i>Surg Obes Relat Dis</i> 2020; 16 (5): 607-613.
547	
548	

ApoM 0.01 (-0.17;0.14) 1		Adiponectin (µg/mL)	ApoM (mg/L)	HOMA-IR
HOMA-IR -0.19 (-0.33;-0.04)* -0.29 (-0.42;-0.14)**** 1 nsulin -0,17 (-0.32;-0.02) -0.31 (-0.44;-0.161)****	Adiponectin	1	_	-
nsulin-0,17 (-0.32;-0.02)-0.31 (-0.44;-0.161)***Slucose-0.06 (-0.21;0.09)-0.085 (-0.234;0.068)BMI-0.21 (-0.35;-0.06)*-0.05 (-0.20;0.10)0.43 (0.30;0.55)***Waist circumference-0.25 (-0.38;-0.10)**-0.11 (-0.29;0.04)0.49 (0.36;0.60)***Fat mass percent-0.09 (-0.25;0.07)-0.26 (-0.40;-0.10)**0.42 (0.28;0.54)***Triglycerides-0.30 (-0.43;-0.15)***-0.01 (-0.16;0.15)0.41 (0.28;0.53)***Total cholesterol0.13 (-0.03;0.27)0.36 (0.22;0.48)***-0.05 (-0.20;0.10)LDL-C0.09 (0.07;0.23)0.27 (0.12;0.40)**-0.05 (-0.20;0.10)HDL-C0.41 (0.27;0.53)***0.32 (0.17;0.45)***-0.34 (-0.47;-0.20)**ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)*0.14 (0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)*0.28 (0.13;0.41)***ns-CRP-0.22 (-0.36;-0.07)*-0.28 (-0.42;-0.13)***0.30 (0,15;0.43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22) <td>АроМ</td> <td>-0.01 (-0.17;0.14)</td> <td>1</td> <td>_</td>	АроМ	-0.01 (-0.17;0.14)	1	_
Glucose -0.06 (-0.21;0.09) -0.085 (-0.234;0.068) BMI -0.21 (-0.35;-0.06)* -0.05 (-0.20;0.10) 0.43 (0.30;0.55)*** Waist circumference -0.25 (-0.38;-0.10)** -0.11 (-0.29;0.04) 0.49 (0.36;0.60)*** Fat mass percent -0.09 (-0.25;0.07) -0.26 (-0.40;-0.10)** 0.42 (0.28;0.54)*** Triglycerides -0.30 (-0.43;-0.15)*** -0.01 (-0.16;0.15) 0.41 (0.28;0.53)*** Total cholesterol 0.13 (-0.03;0.27) 0.36 (0.22;0.48)*** -0.05 (-0.20;0.10) DL-C 0.09 (0.07;0.23) 0.27 (0.12;0.40)** -0.05 (-0.20;0.10) HDL-C 0.41 (0.27;0.53)*** 0.32 (0.17;0.45)*** -0.34 (-0.47;-0.20)** ApoA-I 0.34 (0.19;0.46)*** 0.32 (0.17;0.45)*** -0.26 (-0.40;-0.11)** ApoB100 -0.06 (-0.21;0.09) 0.20 (0.04;0.34)* 0.14 (-0.01;0.29) ApoC-III 0.06 (-0.03;0.21) 0.19 (0.04;0.34)* 0.30 (0,15;0,43)*** γ-GT -0.14 (-0.29;0.01) -0.04 (-0.19;0.11) 0.41 (0.27;0.53)*** Age 0.09 (-0.06;0.24) -0.25 (-0.38;-0.11)** 0.08 (-0.07;0.23) Alcohol -0.01 (-0.16;0.14) 0.19 (0.04;0.34)* -0.03 (-0.18;0.12) <	HOMA-IR	-0.19 (-0.33;-0.04)*	-0.29 (-0.42;-0.14)***	1
BMI $-0.21 (-0.35; -0.06)^*$ $-0.05 (-0.20; 0.10)$ $0.43 (0.30; 0.55)^{***}$ Waist circumference $-0.25 (-0.38; -0.10)^{**}$ $-0.11 (-0.29; 0.04)$ $0.49 (0.36; 0.60)^{***}$ Fat mass percent $-0.09 (-0.25; 0.07)$ $-0.26 (-0.40; -0.10)^{**}$ $0.42 (0.28; 0.54)^{***}$ Triglycerides $-0.30 (-0.43; -0.15)^{***}$ $-0.01 (-0.16; 0.15)$ $0.41 (0.28; 0.53)^{***}$ Total cholesterol $0.13 (-0.03; 0.27)$ $0.36 (0.22; 0.48)^{***}$ $-0.05 (-0.20; 0.10)$ LDL-C $0.09 (0.07; 0.23)$ $0.27 (0.12; 0.40)^{**}$ $-0.05 (-0.20; 0.10)$ HDL-C $0.41 (0.27; 0.53)^{***}$ $0.32 (0.18; 0.45)^{***}$ $-0.34 (-0.47; -0.20)^{**}$ ApoA-I $0.34 (0.19; 0.46)^{***}$ $0.32 (0.17; 0.45)^{***}$ $-0.26 (-0.40; -0.11)^{**}$ ApoA-I $0.36 (-0.03; 0.21)$ $0.19 (0.04; 0.34)^{**}$ $0.14 (-0.01; 0.29)$ ApoC-III $0.06 (-0.03; 0.21)$ $0.19 (0.04; 0.34)^{**}$ $0.30 (0,15; 0,43)^{***}$ γ -GT $-0.14 (-0.29; 0.01)$ $-0.04 (-0.19; 0.11)$ $0.41 (0.27; 0.53)^{***}$ Age $0.09 (-0.06; 0.24)$ $-0.25 (-0.38; -0.11)^{**}$ $0.08 (-0.07; 0.23)$ Alcohol $-0.01 (-0.16; 0.14)$ $0.19 (0.04; 0.34)^{*}$ $-0.03 (-0.18; 0.12)$ Simoking $0.04 (-0.11; 0.19)$ $0.02 (-0.13; 0.17)$ $0.05 (-0.11; 0.20)$ Physical activity $0.05 (-0.10; 0.20)$ $0.01 (-0.15; 0.16)$ $-0.26 (-0.39; -0.11)^{**}$ Systolic blood pressure $-0.03 (-0.18; 0.12)$ $0.03 (-0.12; 0.19)$ $0.07 (-0.08; 0.22)$	Insulin	-0,17 (-0.32;-0.02)	-0.31 (-0.44;-0.161)***	_
Waist circumference -0.25 (-0.38;-0.10)** -0.11 (-0.29;0.04) 0.49 (0.36;0.60)*** Fat mass percent -0.09 (-0.25;0.07) -0.26 (-0.40;-0.10)** 0.42 (0.28;0.54)*** Triglycerides -0.30 (-0.43;-0.15)*** -0.01 (-0.16;0.15) 0.41 (0.28;0.53)*** Total cholesterol 0.13 (-0.03;0.27) 0.36 (0.22;0.48)*** -0.05 (-0.20;0.10) LDL-C 0.09 (0.07;0.23) 0.27 (0.12;0.40)** -0.05 (-0.20;0.10) HDL-C 0.41 (0.27;0.53)*** 0.32 (0.18;0.45)*** -0.34 (-0.47;-0.20)** ApoA-I 0.34 (0.19;0.46)*** 0.32 (0.17;0.45)*** -0.26 (-0.40;-0.11)** ApoB100 -0.06 (-0.21;0.09) 0.20 (0.04;0.34)* 0.14 (-0.01;0.29) ApoC-III 0.06 (-0.03;0.21) 0.19 (0.04;0.34)* 0.30 (0,15;0.43)*** ny-GT -0.14 (-0.29;0.01) -0.04 (-0.19;0.11) 0.41 (0.27;0.53)*** Age 0.09 (-0.06;0.24) -0.25 (-0.38;-0.11)** 0.08 (-0.07;0.23) Alcohol -0.01 (-0.16;0.14) 0.19 (0.04;0.34)* -0.03 (-0.18;0.12) Smoking 0.04 (-0.11;0.19) 0.02 (-0.13;0.17) 0.05 (-0.11;0.20) Phys	Glucose	-0.06 (-0.21;0.09)	-0.085 (-0.234;0.068)	_
Fat mass percent-0.09 (-0.25;0.07)-0.26 (-0.40;-0.10)**0.42 (0.28;0.54)***Triglycerides-0.30 (-0.43;-0.15)***-0.01 (-0.16;0.15)0,41 (0.28;0.53)***Total cholesterol0.13 (-0.03;0.27)0.36 (0.22;0.48)***-0.05 (-0.20;0.10)LDL-C0.09 (0.07;0.23)0.27 (0.12;0.40)**-0.05 (-0.20;0.10)HDL-C0.41 (0.27;0.53)***0.32 (0.18;0.45)***-0.34 (-0.47;-0.20)**ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)**0.38 (0.15;0,43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	BMI	-0.21 (-0.35;-0.06)*	-0.05 (-0.20;0.10)	0.43 (0.30;0.55)***
Triglycerides-0.30 (-0.43;-0.15)***-0.01 (-0.16;0.15)0,41 (0.28;0.53)***Total cholesterol0.13 (-0.03;0.27)0.36 (0.22;0.48)***-0.05 (-0.20;0.10)LDL-C0.09 (0.07;0.23)0.27 (0.12;0.40)**-0.05 (-0.20;0.10)HDL-C0.41 (0.27;0.53)***0.32 (0.18;0.45)***-0.34 (-0.47;-0.20)**ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)*0.32 (0.15;0.43)***hs-CRP-0.22 (-0.36;-0.07)*-0.28 (-0.42;-0.13)***0,30 (0,15;0.43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Waist circumference	-0.25 (-0.38;-0.10)**	-0.11 (-0.29;0.04)	0.49 (0.36;0.60)***
Total cholesterol0.13 (-0.03;0.27)0.36 (0.22;0.48)***-0.05 (-0.20;0.10)LDL-C0.09 (0.07;0.23)0.27 (0.12;0.40)**-0.05 (-0.20;0.10)HDL-C0.41 (0.27;0.53)***0.32 (0.18;0.45)***-0.34 (-0.47;-0.20)**ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)**0.28 (0.13;0.41)***ns-CRP-0.22 (-0.36;-0.07)*-0.28 (-0.42;-0.13)***0,30 (0,15;0,43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Fat mass percent	-0.09 (-0.25;0.07)	-0.26 (-0.40;-0.10)**	0.42 (0.28;0.54)***
LDL-C0.09 (0.07;0.23)0.27 (0.12;0.40)**-0.05 (-0.20;0.10)HDL-C0.41 (0.27;0.53)***0.32 (0.18;0.45)***-0.34 (-0.47;-0.20)**ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.3;0.21)0.19 (0.04;0.34)*0.28 (0.13;0.41)***hs-CRP-0.22 (-0.36;-0.07)*-0.28 (-0.42;-0.13)***0,30 (0,15;0.43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.02 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Triglycerides	-0.30 (-0.43;-0.15)***	-0.01 (-0.16;0.15)	0,41 (0.28;0.53)***
HDL-C0.41 (0.27;0.53)***0.32 (0.18;0.45)***-0.34 (-0.47;-0.20)**ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)**0.28 (0.13;0.41)***hs-CRP-0.22 (-0.36;-0.07)*-0,28 (-0.42;-0.13)***0,30 (0,15;0,43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Total cholesterol	0.13 (-0.03;0.27)	0.36 (0.22;0.48)***	-0.05 (-0.20;0.10)
ApoA-I0.34 (0.19;0.46)***0.32 (0.17;0.45)***-0.26 (-0.40;-0.11)**ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)**0.28 (0.13;0.41)***hs-CRP-0.22 (-0.36;-0.07)*-0,28 (-0.42;-0.13)***0,30 (0,15;0,43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	LDL-C	0.09 (0.07;0.23)	0.27 (0.12;0.40)**	-0.05 (-0.20;0.10)
ApoB100-0.06 (-0.21;0.09)0.20 (0.04;0.34)**0.14 (-0.01;0.29)ApoC-III0.06 (-0.03;0.21)0.19 (0.04;0.34)*0.28 (0.13;0.41)***hs-CRP-0.22 (-0.36;-0.07)*-0,28 (-0.42;-0.13)***0,30 (0,15;0,43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	HDL-C	0.41 (0.27;0.53)***	0.32 (0.18;0.45)***	-0.34 (-0.47;-0.20)***
ApoC-III $0.06 (-0.03; 0.21)$ $0.19 (0.04; 0.34)^*$ $0.28 (0.13; 0.41)^{***}$ hs-CRP $-0.22 (-0.36; -0.07)^*$ $-0,28 (-0.42; -0.13)^{***}$ $0,30 (0,15; 0,43)^{***}$ γ -GT $-0.14 (-0.29; 0.01)$ $-0.04 (-0.19; 0.11)$ $0.41 (0.27; 0.53)^{***}$ Age $0.09 (-0.06; 0.24)$ $-0.25 (-0.38; -0.11)^{**}$ $0.08 (-0.07; 0.23)$ Alcohol $-0.01 (-0.16; 0.14)$ $0.19 (0.04; 0.34)^*$ $-0.03 (-0.18; 0.12)$ Smoking $0.04 (-0.11; 0.19)$ $0.02 (-0.13; 0.17)$ $0.05 (-0.11; 0.20)$ Physical activity $0.05 (-0.10; 0.20)$ $0.01 (-0.15; 0.16)$ $-0.26 (-0.39; -0.11)^{**}$ Systolic blood pressure $-0.03 (-0.18; 0.13)$ $-0.12 (-0.27; 0.03)$ $0.07 (-0.08; 0.22)$	ApoA-I	0.34 (0.19;0.46)***	0.32 (0.17;0.45)***	-0.26 (-0.40;-0.11)***
hs-CRP-0.22 (-0.36;-0.07)*-0,28 (-0.42;-0.13)***0,30 (0,15;0,43)***γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	АроВ100	-0.06 (-0.21;0.09)	0.20 (0.04;0.34)**	0.14 (-0.01;0.29)
γ-GT-0.14 (-0.29;0.01)-0.04 (-0.19;0.11)0.41 (0.27;0.53)***Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	ApoC-III	0.06 (-0.03;0.21)	0.19 (0.04;0.34)*	0.28 (0.13;0.41)***
Age0.09 (-0.06;0.24)-0.25 (-0.38;-0.11)**0.08 (-0.07;0.23)Alcohol-0.01 (-0.16;0.14)0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	hs-CRP	-0.22 (-0.36;-0.07)*	-0,28 (-0.42;-0.13)***	0,30 (0,15;0,43)***
Alcohol-0.01 (-0.16;0.14) 0.19 (0.04;0.34)*-0.03 (-0.18;0.12)Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16) -0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	γ-GT	-0.14 (-0.29;0.01)	-0.04 (-0.19;0.11)	0.41 (0.27;0.53)***
Smoking0.04 (-0.11;0.19)0.02 (-0.13;0.17)0.05 (-0.11;0.20)Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Age	0.09 (-0.06;0.24)	-0.25 (-0.38;-0.11)**	0.08 (-0.07;0.23)
Physical activity0.05 (-0.10;0.20)0.01 (-0.15;0.16)-0.26 (-0.39;-0.11)**Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Alcohol	-0.01 (-0.16;0.14)	0.19 (0.04;0.34)*	-0.03 (-0.18;0.12)
Systolic blood pressure-0.03 (-0.18;0.13)-0.12 (-0.27;0.03)0.07 (-0.08;0.22)Diastolic blood pressure-0.03 (-0.18;0.12)0.03 (-0.12;0.19)0.07 (-0.08;0.22)	Smoking	0.04 (-0.11;0.19)	0.02 (-0.13;0.17)	0.05 (-0.11;0.20)
Diastolic blood pressure -0.03 (-0.18;0.12) 0.03 (-0.12;0.19) 0.07 (-0.08;0.22)	Physical activity	0.05 (-0.10;0.20)	0.01 (-0.15;0.16)	-0.26 (-0.39;-0.11)***
	Systolic blood pressure	-0.03 (-0.18;0.13)	-0.12 (-0.27;0.03)	0.07 (-0.08;0.22)
Resting heart rate0.11 (-0.06;0.25)-0.15 (-0.29;0.01) 0.23 (0.08;0.37)**	Diastolic blood pressure	-0.03 (-0.18;0.12)	0.03 (-0.12;0.19)	0.07 (-0.08;0.22)
	Resting heart rate	0.11 (-0.06;0.25)	-0.15 (-0.29;0.01)	0.23 (0.08;0.37)**

Table 1. Spearman correlation coefficients of adiponectin, apoM and HOMA-IR with anthropometric parameters, biological markers and environmental factors in cohort A

549 Tables

550 Spearman rank correlation (95% confidence interval), n=169.

551 *FDR<0.05, ** FDR <0.01, *** FDR <0.001. FDR < 0.05 are indicated in bold.

552 ApoA-I: apolipoprotein A-I; ApoB-100: apolipoprotein B100; ApoC-III: apolipoprotein C-III; BMI, body mass index;

553 FDR, false discovery rate; hs-CRP, high-sensitivity C-reactive protein; γ-GT, gamma glutamyl transferase; HDL-C,

- 554 high-density lipoprotein-cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; LDL-C, low-
- 555 density lipoprotein-cholesterol.
- 556

Table 2. Multiple linear regression analysis on HOMA-IR in cohort A

R ² =39			
β estimate	SE	P-value	% ^b
-0.133	0.045	0.0035	5.6
0.177	0.046	0.0002	13.6
0.181	0.046	0.0001	9.6
1.421	0.044	0.0016	4.5
0.353	0.132	0.0084	2.8
	β estimate -0.133 0.177 0.181 1.421	β estimate SE -0.133 0.045 0.177 0.046 0.181 0.046 1.421 0.044	β estimateSEP-value-0.1330.0450.00350.1770.0460.00020.1810.0460.00011.4210.0440.0016

557 Variables at entry: Adiponectin, apoC-III, apoB-100, apoM, BMI, γ -GT, hs-CRP, HDL-C, physical activity, 558 triglycerides, waist circumference, diabetes (fasting blood glucose \geq 7.0 mmol/L or treatment *vs.* no), 559 dyslipidemia (total cholesterol \geq 2.50 g/L or treatment), hypertension (systolic blood pressure \geq 140 mmHg or 560 diastolic blood pressure \geq 90 mmHg or treatment) and case-control status. Continuous variables were 561 standardised. β estimates were given for one standard deviation variation.

^aLog-transformed data; ^bPercentage of variance explained.

563 ApoB-100: apolipoprotein B100; ApoC-III: apolipoprotein C-III; ApoM: apolipoprotein M; BMI: body mass

index; γ-GT: gamma-glutamyltransferase; HDL-C: high-density lipoprotein cholesterol; hs-CRP: high-sensitivity
 C-Reactive Protein; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; LDL-C: low-density

566 lipoprotein cholesterol.

568 Figure Legends

569

Figure 1. Changes in circulating apoM and adiponectin relationship with improvement of insulin sensitivity after bariatric surgery. Sera from 11 obese individuals (cohort B) were tested for apoM (panel A) and adiponectin (panel B) levels before and one year after sleeve gastrectomy. Changes in adipokine concentrations were correlated to the changes in the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index. Data are expressed as percentage change from baseline. Linear correlation coefficients and *P*-values are displayed in each graph. The dotted lines represent 95% confidence intervals.

577

Figure 2. ADIPOQ and APOM gene expression in adipose tissue from overweight and obese individuals. ADIPOQ and APOM mRNA levels were measured in subcutaneous adipose tissue of 267 men and women with overweight or obesity (cohort C). Linear regression analysis of ADIPOQ and APOM gene expression (panel A). Linear regression of APOM (panel B) and ADIPOQ (panel C) gene expression to HOMA-IR. Linear correlation coefficient and *P*-value are presented. Dotted lines represent 95% confidence interval.

584


585 Figure 3. Inflammatory factors downregulate ADIPOQ and APOM gene expression in adipocytes.

586 Effect of conditioned media from non-polarized, M2-like polarized or M1-like polarized ThP-1 cells on 587 ADIPOQ gene expression in hMADS adipocytes (panel A). Association between ADIPOQ and APOM 588 gene expression in hMADS adipocytes treated for 48 h with conditioned media from non-polarized 589 (grey dots), M2-like polarized (black dots) or M1-like polarized (white dots) ThP-1 cells (panel B). 590 ADIPOQ and APOM gene expression in hMADS adipocytes after C-reactive protein treatment for 48 h 591 (panel C). Association between ADIPOQ and APOM gene expression in hMADS adipocytes treated for 592 48 h with C-reactive protein (panel D). Results are presented as mean \pm SD of 3 independent 593 experiments (panels A and C). Linear correlation coefficients and P-values are displayed in each

- 594 graph. The dotted lines represent 95% confidence intervals (panels B and D). Data were analysed by
- 595 Kruskal-Wallis test (panels A and C). **P*<0.05. ***P*<0.01.

- 597 Figure 4. Adiponectin upregulates *APOM* gene expression in adipocytes.
- 598 APOM mRNA level upon 48 h of globular adiponectin treatment in hMADS adipocytes. Results are
- 599 presented as mean ± SD of 3 independent experiments. Data were analysed by Kruskal-Wallis test.
- 600 **P*<0.05. ***P*<0.01.

Figure 1



Change in HOMA-IR (%)

Figure 2






Figure 3




Figure 4

